June 2023: Introducing the ultra-high throughput MGI DNBSEQ-T7 sequencer at Alacris!
Prepare to be amazed as Alacris unleashes the impressive capabilities of the ultra-high throughput MGI DNBSEQ-T7 sequencer. Together with the DNBSEQ-G400 instruments, the MGI platform empowers us to provide customized NGS solutions that offer the best value without compromising on quality, catering to a vast array of clinical and research applications to meet the diverse needs of our clients.
May 2023: Alacris Extends ISO15189 Accreditation for its Alacris CMTA® Cancer Diagnostic test with Illumina and MGI NGS Technologies!
We are thrilled to announce that Alacris has taken a great leap forward in molecular cancer diagnostics by extending its ISO15189 accreditation to include both Illumina and MGI NGS technologies. This exciting development allows us to harness the exceptional power of MGI DNBSETM technology for delivering cutting-edge medical Dx services with outstanding quality, accuracy and flexibility.
Join us on this remarkable journey as Alacris continues to pave the way in next-generation cancer Dx, setting new standards of excellence and innovation.
We are now accepting samples! Request a quote today.
The benefits of comprehensive molecular tumor and micorenvironment profiling for treatment recommendations are increasingly recognized, opening up a novel dimension in personalized oncology. more…
Digital Twins to help virtualise drug development:
ModCell™ is an innovative tool designed to model the tumor response to specific therapies or therapy combinations based on deep omics data.
A unique opportunity to virtualise and accelerate drug discovery and development. more…